Considerations for Choosing Soluble Immune Markers to Determine Safety of Novel Vaginal Products
- PMID: 36303630
- PMCID: PMC9580790
- DOI: 10.3389/frph.2022.899277
Considerations for Choosing Soluble Immune Markers to Determine Safety of Novel Vaginal Products
Abstract
Several soluble cytokines have been associated with microbicide-induced cervicovaginal inflammation, non-optimal vaginal microbiota, and risk of HIV acquisition. Many of these biomarkers are used in preclinical assays to estimate the safety of vaginally applied products. However, there are currently no validated biomarkers to evaluate the safety of novel vaginal products in clinical trials. This hinders the rapid and rational selection of novel products being tested in first-in-human trials. We reviewed available literature to assess how best to select and measure soluble immune markers to determine product safety in first in human clinical trials of novel vaginal products.
Keywords: cytokines; female genital tract; live biotherapeutics; product development; safety.
Copyright © 2022 Happel, Sivro, Liebenberg, Passmore and Mitchell.
Conflict of interest statement
JP holds a patent for a Method for diagnosing an inflammatory condition in the female genital tract (EP3063542B1). CM receives grant funding from Merck, and has served as a consultant for Scynexis, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
Biomarkers of cervicovaginal inflammation for the assessment of microbicide safety.Sex Transm Dis. 2009 Mar;36(3 Suppl):S84-91. doi: 10.1097/OLQ.0b013e3181994191. Sex Transm Dis. 2009. PMID: 19218890 Review.
-
Evaluation of immunological markers of ovine vaginal irritation: Implications for preclinical assessment of non-vaccine HIV preventive agents.J Reprod Immunol. 2017 Nov;124:38-43. doi: 10.1016/j.jri.2017.09.014. Epub 2017 Oct 13. J Reprod Immunol. 2017. PMID: 29054075 Free PMC article.
-
Safety analysis of the diaphragm in combination with lubricant or acidifying microbicide gels: effects on markers of inflammation and innate immunity in cervicovaginal fluid.Am J Reprod Immunol. 2009 Feb;61(2):121-9. doi: 10.1111/j.1600-0897.2008.00670.x. Am J Reprod Immunol. 2009. PMID: 19143675 Free PMC article. Clinical Trial.
-
Clinical development of microbicides for the prevention of HIV infection.Curr Pharm Des. 2004;10(3):315-36. doi: 10.2174/1381612043386374. Curr Pharm Des. 2004. PMID: 14754390 Review.
-
Distinct Immune Responses Elicited From Cervicovaginal Epithelial Cells by Lactic Acid and Short Chain Fatty Acids Associated With Optimal and Non-optimal Vaginal Microbiota.Front Cell Infect Microbiol. 2020 Jan 10;9:446. doi: 10.3389/fcimb.2019.00446. eCollection 2019. Front Cell Infect Microbiol. 2020. PMID: 31998660 Free PMC article.
Cited by
-
Update on the Impact of Depot Medroxyprogesterone Acetate on Vaginal Mucosal Endpoints and Relevance to Sexually Transmitted Infections.Curr HIV/AIDS Rep. 2023 Aug;20(4):251-260. doi: 10.1007/s11904-023-00662-0. Epub 2023 Jun 21. Curr HIV/AIDS Rep. 2023. PMID: 37341916 Free PMC article. Review.
References
-
- O'Hanlon DE, Brown SE, He X, Stennett CA, Robbins SJ, Johnston ED, et al. . Observational cohort study of the effect of a single lubricant exposure during transvaginal ultrasound on cell-shedding from the vaginal epithelium. PLoS ONE. (2021) 16:e0250153. 10.1371/journal.pone.0250153 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources